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Abstract - Aim: To explore the association between alexithymia and two dimensions of major depressive 
disorder (MDD): cognitive and somatic-affective. Patients and methods. Unicentric, cross-sectional study in-
cluded consecutive sample of 63 patients at the Department of Psychiatry (DoP), Sestre Milosrdnice Univer-
sity Hospital Centre, Zagreb, Croatia. Target population included outpatients with diagnosed MDD (F32 and 
F33, according to ICD-10). Inclusion critieria were: confirmed MDD diagnosis, age between 18 and 65 years, 
both genders, outpatient treatment at the DoP. The main outcome was the association between alexithymia, 
measured by total score on 20-item Toronto-Alexithymia scale (TAS-20), with two dimensions of MDD, cog-
nitive and somatic-affective, measured by Beck Depression Inventory-II (BDI-II). Results: Both dimensions of 
BDI-II and the total severity of MDD symptoms were statistically significantly, although low, associated with 
alexithymia, and the differences between these two correlations were not (statistically) significant. However, 
in the multivariable model, the cognitive dimension (b = 0.64; β = 0.48; p = 0.002; statistically significant at 
the false discovery rate of 0.05) was primarily associated with alexithymia, and the somatic-affective was 
not, after all cognitive aspects were controlled for (b = -0.19; β = 0-0.14; p = 0.491; not statistically significant, 
with the false discovery rate of 0.05). Conclusion: Alexithymia is primarily associated with a pure cognitive 
dimension of MDD after somatic-affective elements are excluded. Somatic-affective dimension of MDD is not 
associated with alexithymia after the cognitive elements were controlled for. Both dimensions, as well as the 
overall severity of MDD, are associated with alexithymia, but this association is relatively low.
Key words: alexithymia, depression, major depressive disorder, cognitive dimension, somatic-affective di-
mension
Introduction
Major depressive disorder (MDD) is the 
affective disorder characterised by three 
groups of  depressive symptoms: emotional, 
cognitive and somatic. It is frequently ac-
companied with chronicity, somatic and/or 
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psychiatric comorbidity, difficulties in func-
tioning as well as quality of  life decrease [1]. 
According to World Health Organization 
(WHO), currently in the world 322 millions 
of  people suffer from depression [2]. Preva-
lence of  MDD in Croatia is similar to those 
in other European neighbour countries, and 
was in previous years estimated by the Croa-
tian Institute for Public Health (CIPH). Be-
tween 2014 and 2015, CIPH performed Eu-
ropean Health Interview Survey (EHIS), as 
well as use of  Patient Health Questionnaire-8 
item (PHQ-8) within it. This Questionnaire 
was used as a triage instrument for possible 
depression for studies on non-clinical popu-
lation. This self-rating instrument (PHQ-8) 
results certainly call for further clinical-psy-
chiatric evaluation, collection of  heteroan-
amnestic data as well as differential-diagnos-
tic process. According to CIPH data, 1.5% 
of  surveyed population met criteria for major 
depressive episode, while 2.3% met criteria 
for some other depressive disorder. In addi-
tion, 96 % of  surveyed population did not 
met criteria for depressive disorder [3]. The 
term “alexithymia” is related to difficulties in 
recognizing and description of  feelings [4]. It 
is a reflection of  difficulties in cognitive-emo-
tional processing and emotion control [5], 
and it can result in poorer understanding oth-
er people’s emotions. Alexithymia prevalence 
in general population is about 10%, while in 
patients with MDD could be up to 40 % [6]. 
Causes of  alexithymia are not clarified yet. 
According to big Danish twins study, it seems 
that about 30-33 % of  alexithymia is herita-
ble [7]. Different previous studies found the 
association between alexithymia and MDD 
[8]. Clinical investigations, as well as every-
day practice, suggest that MDD includes het-
erogeneous set of  symptoms, and it seems 
that it could include various syndromes [9]. 
Based on such estimations, we decided to in-
vestigate the association between alexithymia 
and two dimensions of  MDD: cognitive and 
somatic-affective. The aim of  this study was 
to investigate the association of  alexithymia, 
measured with 20-item Toronto Alexithymia 
Scale (TAS-20), with two MDD dimensions, 
measured with Beck Depression Inventory-
II (BDI-II).
Patients and Methods
A unicentric, observational, cross-sec-
tional study was performed between April 
and June 2019 at the Department of  Psy-
chiatry, Sestre Milosrdnice University Hos-
pital Centre, Zagreb, Croatia. Prior to study 
procedure, the Ethics Committee Approval 
was obtained, in accordance to Helsinki Dec-
laration of  World Health Organization [10]. 
Informed consent was signed by each par-
ticipant prior to the study procedure. Target 
population included persons in the outpatient 
treatment with diagnosed MDD (categories: 
F 32 and F 33, according to International 
Classification of  Diseases, 10th Revision - 
ICD-10) [11]. Inclusion criteria included: 
confirmed MDD diagnosis, age between 18 
and 65 years, both genders, outpatient treat-
ment at the Department of  Psychiatry. Ex-
clusion criteria were: inability to use select-
ed psychometric instruments and refusal 
for participation in the study. None of  the 
screened patients met exclusion criteria. The 
consecutive sample was selected according to 
the time patients arrived to their outpatient 
treatment. Target statistical power was deter-
mined at 80 %, while the level of  statistical 
significance at p<0.05. Minimal association 
between alexithymia and two MDD dimen-
sions that was considered clinically and the-
oretically relevant and which was wanted to 
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be statistically significantly confirmed/tested 
was determined as Spearman’s coefficient of  
range correlation ρ=0.35. Moreover, accord-
ing to this presumption, target sample was 
to include 61 participants. With anticipated 
/calculated up to 5 % of  wrong or incom-
pletely filled data, the initial target size sam-
ple was increased to 66 participants. Sample 
size was calculated using computer program: 
G*Power version 3.1.9.2. The main outcome 
was the association between alexithymia, 
measured with total 20-item Toronto Alexi-
thymia Scale (TAS-20) [12], and two MDD 
dimensions, measured by Beck Depression 
Inventory-II (BDI-II) [13]. Taylor and asso-
ciates developed TAS-26 scale in 1985 [14]. 
The original 26 item scale was modified by 
Horton, Gewirtz and Kreutter in 1992 [15] 
and Bagly and associates in 1994 [16,17], into 
TAS-20. TAS-20 is a 20-item scale containing 
five-degree Likert-type ascertainments, from: 
“completely disagree”, via neutral “neither 
agree nor disagree” to “completely agree”. 
Each participant evaluates to which extent 
each statement (within single item) is related 
to him/her. TAS-20 has a three-factor struc-
ture, theoretically consistent with alexithymia 
construct. Three factors include: (i) difficul-
ties in identifying feelings and their distinc-
tion from somatic sensations, (ii) difficulties 
in describing feelings, and (iii) externally-
oriented thinking. Yet, the main distinction 
between two versions of  TAS instrument is 
in gawing up on dimension of  “daily dream-
ing” in TAS-20. Despite more factor purity 
of  such modified scale, as well as better other 
metrical characteristics, the modification may 
decrease scale validity in relation to original 
alexithymia concept [18]. The original version 
– TAS-26 – was validated in Croatian sample 
[18], while TAS-20, although without formal-
ly done validation study, was many time used 
in studies of  various Croatian population 
samples. In our study, alexithymia was anal-
ysed as a total score on TAS-20. Two MDD 
dimensions were measured by BDI-II: a) cog-
nitive dimension and b) somatic-affective di-
mension [13]. BDI-II was validated in Croa-
tian, as well [19]. First scale was developed by 
Beck in 1961 [20]. After that, several modifi-
cations were done. The 21 item version used 
in our investigation was constructed in 1996 
[13], and for each item patients rate various 
MDD symptom severity, by choosing one 
from four possible answers. Two-factors or 
two-dimensional BDI-II structure was con-
firmed in various studies [21]. Cognitive di-
mension of  MDD is measured by followed 
BDI-II items: 1. sadness, 2. pessimism, 3. 
past failure, 5. guilty feelings, 6. punishment 
feelings, 7. self-dislike, 8. self-criticalness, 9. 
suicidal thoughts, 13. indecisiveness and 14. 
worthlessness. Somatic-affective dimension 
is measured by items: 4. loss of  pleasure, 10. 
crying, 11. agitation, 12. loss of  interest, 15. 
loss of  energy, 16. changes in sleeping pat-
tern, 17. irritability, 18. changes in appetite, 
19. concentration difficulty, 20. fatigue, 21. 
loss of  interest in sex. Regarding our sta-
tistical analysis, the (main) hypothesis was 
checked by Spearman’s coefficient of  range 
correlation. Numerical variables distributions 
were described by median and interquartile 
range (IQR) and were presented by histo-
grams and box-and-whiskers. The statisti-
cal significance of  differences in arithmetic 
mean of  results on TAS-20 between separate 
participants groups was calculated by analysis 
of  variance.
Results
Three from 66 initially included patients 
did not fill TAS-20 adequately and therefore 
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were excluded from final analysis. Final anal-
ysis was done only with data from patients 
that had all the items answered, per protocol. 
Of  63 patients with all items answered, 42 
were women (66.7 %) (Table 1). Age ranged 
from 24 to 64 years, while median (IQR) was 
53 (47-59) years.
MDD duration median (IQR) in our sam-
ple was 4 (2-6) years (Table 2). Most of  the 
patients/participants were treated with selec-
tive serotonin reuptake inhibitors, 27 (42.9 
%), more than 90 % with benzodiazepines, 
while nine (14.3 %) of  them even with anti-
psychotics.
Table 1. Sociodemographic and vital participant characteristics (n=63)
n (%)
Age (years), median (IQR) 53 (47-59)
Gender
 male 21 (33.3)
 female 42 (66.7)
Education
 elementary and high school
 college 47 (74.6)
Marital status 16 (25.4)
 married or in a stabile emotional relationship 45 (71.4)
 never married, without partner 18 (28.6)
Number of  household members, median (IQR) 3 (2-4)
Working status
 employed or students 40 (64.5)
 unemployed or retired 22 (35.5)
Monthly household income  
per one member (HRK), median (IQR) 2.333 (1.286-3.500)
Chronic somatic illness 43 (68.3)
Body mass index (kg/m2), 
median (IKR) 27 (24-30)
Body mass index (kg/m2)
 normal (<25.0) 19 (30.2)
 overweight (25,0-29,9) 28 (44.4)
 obese (≥30,0) 16 (25.4)
Smoking tobacco 29 (46.0)
Data presented as number (percentage) of  participants if  not otherwise stated
Abbreviation: IQR = interquartile range
There were no data regarding working status for one (1,5%) participant.
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Alexithymia
TAS results distribution did not statisti-
cal significantly deviate from normal (shap-
iro-Wilk test, p=0.838) (Table 3). Arithmetic 
mean (standard deviation) of  results on TAS-
20 was 60 (8.7), with total range of  all results 
from 40 to 80.
No statistically significant difference in 
TAS-20 results between analysed participants 
group was found (Table 3).
The association between alexithymia and total 
BDI-II result
Total result on BDI-II severity of  depres-
sion scale and result on TAS-20 alexithymia 
Table 2. Participants clinical characteristics (n=63)
n (%)
MDD duration in years, median (IQR) 4 (2-6)
Antidepressants in therapy  
(number of  medication)
 monotherapy 56 (88.9)
 combination of  two or more agents 7 (11.1)
Antidepressants in therapy 
 SSRI 27 (42.9)
 SNRI 14 (22.2)
 NaSSA 12 (19.0)
 MSS 9 (14.3)
 TCA 7 (11.1)
 MGS 3 (4.8)
Daily antidepressant dose (fluoxetine 40 mg
equivalents), median (IQR) 24 (20-41)
Benzodiazepines in therapy 58 (92.1)
Therapy with particular benzodiazepines
 alprazolam 16 (25.4)
 diazepam 32 (50.8)
 other 10 (15.9)
Therapy with antipsychotics 9 (14.3)
Psychotherapy 47 (74.6)
Data presented as number (percentage) of  participants if  not otherwise stated
Abbreviations: IQR = interquartile range; SSRI = Selective serotonin reuptake inhibitors; SNRI = 
serotonin-norepinephrine reuptake inhibitors; NaSSA = noradrenergic and specific serotonergic anti-
depressants; MSS = Serotonergic system modulators; TCA = tricyclic antidepressants; MGS = Gluta-
matergic system modulators. 
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Figure 1. MDD duration distribution in years from first diagnose with normal distribution 
curve (n=63)
Figure 2. TAS-20 results distribution with normal distribution curve (n=63)
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Figure 3. TAS-20 results distribution diagram of  rectangles; bottom line is 1.5 IQR below 
the median, rectangle is IQR, the middle line median, and the upper 1.5 IQR above the me-
dian; the vertical axis does not start on zero, but on the smallest result (n=63)
Table 3. Result on TAS-20 in different patient groups (n=63)
n AM (SD) p d FDR
Age (years)
 <45 11 65 (10.3) 0.211 0.46
 45-54 27 60 (9.0)
 ≥55 25 60 (7.3)
Gender
 male 21 60 (8.5) 0.583 0.14
 female 42 61 (8.8)
Education
 elementary or high school 47 61 (8.8) 0.624 0.13
 college 16 60 (8.6)
Marital status
 in stable relationship 45 61 (8.4) 0.395 0.22
 alone 18 59 (9.3)
46
n AM (SD) p d FDR
Number of  household members
 1-2 31 60 (8.0) 0.689 0.22
 3-4 22 61 (9.0)
 ≥5 10 62 (10.6)
Working status
 employed or students 40 59 (8.3) 0.208 0.33
 unemployed or retired 22 62 (9.4)
Monthly household income  
per one member (HRK), median (IQR)
 <2000 27 62 (8.9) 0.118 0.54
 2000-3999 24 61 (8.0)
 ≥4000 12 56 (8.6)
Chronic somatic illness
 no 20 60 (9.5) 0.937 0.00
 yes 43 60 (8.4)
Body mass index (kg/m2)
 normal (<25.0) 19 62 (10.4) 0.428 0.34
 overweight (25,0-29,9) 28 59 (7.3)
 obesity (≥30,0) 16 62 (8.8)
Smoking tobacco
 no 34 61 (7.3) 0.446 0,20
 yes 29 60 (10.1)
Data presented as number (percentage) of  participants if  not otherwise stated
Abbreviations: n = participants number; AM = arithmetic mean; SD = standard deviation; p = statis-
tical significance calculated by variance analysis; d = Cohen’s d calculated as standardized measure of  
effect size; FDR = statistically significant results after correction for false discovery rate.
There were no data regarding working status for 1 (1.5%) participant
Table 3. (continued)
scale were significantly correlated (Spear-
man ρ=0.34; p=0.007) (Figure 4). Despite 
statistically significant, that correlation was 
low.
The association between alexithymia and 
MDD cognitive dimension
Result on BDI-II cognitive dimension 
and result on TAS-20 alexithymia scale were 
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significantly correlated (Spearman’s ρ=0.37; 
p=0.003) (Figure 5). Despite statistical sig-
nificance, that correlation was low.
The association between alexithymia and 
MDD somatic-affective dimension
Result on BDI-II somatic-affective di-
mension and result on TAS-20 alexithymia 
scale were significantly correlated (Spearman’s 
ρ=0.27; p=0.034) (Figure 6). Despite statisti-
cal significance, that correlation was low.
Difference in association between alexithymia 
and cognitive as well as somatic-affective BDI-
II dimension 
On this sample level, correlation between 
TAS-20 and BDI-II somatic-affective di-
mension was lower than correlation between 
TAS-20 and BDI-II cognitive dimension. 
The difference between the two correlations, 
correlation between TAS-20 with BDI-II 
cognitive dimension (ρ=0.37) and with BDI-
II somatic-affective dimension (ρ=0.27), was 
not significant (Z=1.46; p=0.145). Correla-
tion between two BDI-II dimensions was 
ρ=0.84; p<0.001.
But, when in linear multiple regression 
analysis both BDI-II dimensions were im-
plemented together, it was shown that cog-
nitive dimension was independently and 
significantly associated with TAS-20 result 
and even after correction for multiple test-
ing, while somatic-affective was not (Figure 
7). Semipartial correlation between BDI-II 
cognitive dimension and TAS-20 result was 
sp=0.28, while correlation between somatic-
affective dimension and TAS-20 result be-
Figure 4. Dotted diagram of  correlation on TAS-20 and BDI-II (n=63)
48
Archives of Psychiatry Research 2021;57:39-52 Vilibić, Dostal, Karlović
Figure 5. Dotted diagram of  correlation between TAS-20 results and BDI-II cognitive 
dimension (n=63)
Figure 6. Dotted diagram of  correlation between TAS-20 results and BDI-II somatic-af-
fective dimension (n=63)
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came negative, sp=-0.08. This could mean 
that two BDI-II dimensions are associated 
particularly in that variance part which asso-
ciates depression with alexithymia.
Discussion
The most important results review
This investigation found association be-
tween BDI-II cognitive dimension and TAS-
20 result independently regarding BDI-II 
somatic-affective dimension, respectively af-
ter the adjustment for somatic-dimension. 
Bivariably both BDI-II dimensions, as well 
as total depression/depressive symptoms se-
verity measured by BDI-II, were significantly 
- although low - associated with alexithymia 
measured with TAS-20, but the difference 
between bivariable correlations between cog-
nitive and somatic-affective dimensions and 
TAS-20 result was not statistical significantly 
different. There was no difference in TAS-20 
Figure 7. Linear multiple results regression on TAS-20 on two BDI-II dimensions (n=63)
BDI-II dimension b (CI95%) s.e. t Β p FDR* sp
Somatic-affective -0.19 (-0.74-0.36) 0.27 -0.69 -0.14 0.491 - -0.08
Cognitive 0.64 (0.09-1.19) 0.27 2.32 0.48 0.024 significant 0.28
Abbreviations: b = nonstandardised regression coefficient; CI95% = 95% confidence interval of  non-
standardised regression coefficient; s.e. = standard error; β = standardised regression coefficient; t = 
ratio between nonstandardised regression coefficient and its standard error; p = regression coefficient 
statistical significance; FDR = False discovery rate; sp = semipartial correlation between BDI-II di-
mension and TAS-20 result
* FDR = 0.05
results between sociodemographically differ-
ent participants groups.
Comparison with previous investigations
Previous studies were focused on asso-
ciation between alexithymia and total MDD 
severity. American authors in their investiga-
tion published in 2010, on patient population 
aged ≥50 years, regarding association be-
tween alexithymia and depression symptoms 
severity, found independent association be-
tween alexithymia and depression symptoms 
severity, after controlling demographic pa-
rameters (age, gender), cognitive functioning, 
as well as MDD burden. More pronounced 
alexithymia was associated with greater se-
verity of  depressive symptoms. Younger pa-
tients, patients with lower cognitive function-
ing as well as those with more pronounced 
disorder burden, had more pronounced/
more severe depressive symptoms. The au-
thors also found that patients with  higher 
scores/higher sums on Difficulties in recog-
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nising emotions subscale  and on Difficul-
ties in emotions expression subscale, but not 
those with higher scores/sums on Externally 
oriented thinking subscale, had higher total 
BDI-II score. Furthermore, they found that 
in patients older than 50 years alexithymia, 
and particularly difficulties in identification 
and emotions expression, was associated 
with more pronounced/more severe depres-
sive symptoms [22].
Chinese authors metaanalysis from 2015 
similarly showed close association between 
alexithymia, measured with TAS-20 and its 
two subscales: Difficulties identifying feel-
ings subscale and Difficulties in describing 
feelings subscale, and depression [23]. In 
contrast to previous investigations that ex-
plored association between alexithymia and 
total MDD severity, this study aimed to ex-
plore the association between alexithymia 
and two MDD dimensions: cognitive and 
somatic-affective. In our investigation, total 
depressive symptoms severity measured by 
BDI-II were significantly, although low, as-
sociated with alexithymia, measured by TAS-
20. Our investigation found an association 
between cognitive BDI-II dimension and 
TAS-20 result independent regarding BDI-II 
somatic-affective dimension, respectively af-
ter adjustment for somatic-affective dimen-
sion.  Alexithymia could be primarily asso-
ciated with pure MDD cognitive dimension 
after somatic-affective elements are extract-
ed, while MDD somatic-affective dimension 
could not be associated with alexithymia after 
cognitive elements are extracted. This result 
is very important for current, as well as for 
future clinical practice because it determines 
the way and type of  interventions in treat-
ment of  patients with MDD and more pro-
nounced/more severe alexithymia.
Investigation limitations
The first limitation is the weakness in alex-
ithymia measuring/objectification. Despite 
TAS-20 is a well known, widely used and 
even language-standardized alexithymia mea-
sure, various weaknesses of  the construct are 
well described in literature. Among the most 
important that should be mentioned is non-
one-dimensionality. The TAS-20 scale was 
aimed to measure three different alexithymia 
dimensions: difficulty identifying feelings, 
difficulty describing feelings and externally 
oriented thinking. To the last listed TAS-20 
dimension, various conceptual and psycho-
metric reserves are addressed. Second limita-
tion is related to heterogeneity of  our sample, 
or more precisely, the fact that patients were 
included in investigation regardless of  their 
treatment duration and total MDD duration. 
Although alexithymia could be independent 
regarding MDD duration, the result on TAS-
20 might vary in relation to MDD duration, 
course and therapy success. Based on avail-
able literature, one cannot reliably determine 
the probable pertaining systematic error, its 
intensity or influence on our conclusions. In 
future investigations, this problem should 
be analysed on samples large enough with 
an aim to allow stratified analysis within pa-
tient groups with recently diagnosed MDD 
and without antidepressant therapy, groups 
that are treated for a short period of  time, 
groups that are treated for a long period of  
time and successfully, and finally groups with 
treatment resistance.
Conclusion
Alexithymia is primarily associated with 
a pure cognitive dimension of  MDD after 
somatic-affective elements are excluded. So-
matic-affective dimension of  MDD is not as-
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sociated with alexithymia after the cognitive 
elements were controlled for. Both dimen-
sions, as well as the overall severity of  MDD, 
are associated with alexithymia but this asso-
ciation is relatively low.
Psychiatrists, medical nurses and other 
healthcare professionals should be familiar 
with the term “alexithymia”, and all should 
be aware of  limited ability of  patients with 
more intensive alexithymia to recognise and 
verbalize their own feelings. This limited abil-
ity can have direct influence on psychiatric 
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Povezanost aleksitimije i dvije dimenzije velikog depresivnog 
poremećaja: kognitivne i somatsko-afektivne
Sažetak - Cilj. Istražiti povezanost aleksitimije s dvije dimenzije velikog depresivnog poremećaja (VDP): kogni-
tivnom i somatsko-afektivnom. Materijali i metode. Provedeno je unicentrično, presječno istraživanje na su-
sljednom uzorku 63 ispitanika na Klinici za psihijatriju KBC Sestre Milosrdnice, Zagreb, Hrvatska. Ciljana popu-
lacija bili su ambulantno liječeni bolesnici s dijagnosticiranim VDP (MKB-10: F32 i F33). Kriteriji uključivanja 
bili su: potvrđena dijagnoza VDP, dob od 18 do 65 godina, oba spola, ambulantno liječenje na Klinici za 
psihijatriju. Glavni ishod bila je povezanost aleksitimije mjerene ukupnim rezultatom Toronto ljestvice alek-
sitimije-20 (TAS-20) s dvije dimenzije VDP mjerenog Beckovim inventarom depresije-II (BDI-II): kognitivnom 
i somatsko-afektivnom. Rezultati. Istraživanjem se pokazalo da su bivarijabilno obje dimenzije BDI-II, kao i 
ukupna težina simptoma VDP statistički značajno iako nisko povezane s aleksitimijom te da razlike između tih 
dviju korelacija nisu statistički značajne. Međutim, u multivarijabilnom modelu pokazalo se da je s aleksitimi-
jom primarno povezana kognitivna dimenzija (b=0,64; β=0,48; p=0,002; statistički značajno uz stopu lažnih 
otkrića od 0,05), dok somatsko-afektivna to nije, nakon što se iz nje izluče svi kognitivni aspekti (b=-0,19; 
β=0-0,14; p=0,491; nije statistički značajno uz stopu lažnih otkrića od 0,05). Zaključak. Čini se da je aleksiti-
mija primarno povezana s čistom kognitivnom dimenzijom VDP nakon što se iz nje izluče somatsko-afektivni 
elementi, odnosno da somatsko-afektivna dimenzija VDP nije povezana s aleksitimijom nakon što su izlučeni 
kognitivni elementi. Obje dimenzije, kao i ukupna težina VDP, povezani su s aleksitimijom, no ta je povezanost 
razmjerno niska.
Ključne riječi: aleksitimija, depresija, veliki depresivni poremećaj, kognitivna dimenzija, somatsko-afektivna 
dimenzija.
